Pacira BioSciences Welcomes New Talent
Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in the development of innovative non-opioid pain relief therapies, has recently made a significant announcement. The company provided inducement awards to support the onboarding of 15 new employees, marking a substantial step in their commitment to enhancing their workforce and operational capabilities.
Details of the Inducement Awards
On a recent date, Pacira granted stock options and restricted stock units as part of their Amended and Restated 2014 Inducement Plan. This move not only reflects Pacira's growth but is also in line with Nasdaq Listing Rule 5635(c)(4). The awards were ratified by the People & Compensation Committee of the Board of Directors without requiring stockholder approval, providing a clear path for these new hires to receive their awards swiftly.
Structure of the Stock Awards
Out of the 15 new hires, six members were granted stock options to acquire a total of 18,000 shares of Pacira common stock. Additionally, each new employee was awarded restricted stock units for an aggregate of 32,600 shares. The stock options carry a term of 10 years and come with a structured four-year vesting plan designed to promote long-term commitment. Specifically, 25 percent of the options will vest at the end of the first year of employment, while the remaining shares vest in equal quarterly installments over the next three years.
Understanding the Restricted Stock Units
In parallel to the stock options, the restricted stock units represent a promising opportunity for new employees as they correspond to one share of common stock each. Vesting for these units will occur annually in four equal parts, starting on a specific date. Each award is contingent upon the continued employment of the individual with Pacira, which indicates the company's focus on fostering a stable and committed workforce.
About Pacira BioSciences
Pacira BioSciences is dedicated to offering innovative, non-opioid therapies designed to improve patient outcomes. Their portfolio includes three primary non-opioid treatments, namely EXPAREL (bupivacaine liposome injectable suspension), ZILRETTA (triamcinolone acetonide extended-release injectable suspension), and the ioveraº technology, which provides immediate pain relief through targeted cold therapy. In addition to these established treatments, the company is at the forefront of research with PCRX-201, a novel gene therapy aimed at treating widespread diseases such as osteoarthritis.
Connecting with Pacira
To explore more about their innovative solutions or for inquiries, individuals can reach out to the dedicated investor relations or media contacts at Pacira. These communications channels reflect their commitment to transparency and engagement with stakeholders.
Frequently Asked Questions
What is the purpose of the inducement grants by Pacira BioSciences?
The inducement grants are a way to attract and retain top talent by providing new employees with stock options and restricted stock units as a material inducement for joining the company.
What types of awards were given to the new employees?
New employees received stock options and restricted stock units, allowing them to potentially benefit from the company's future growth and success.
How long is the vesting period for the stock options?
The stock options have a 10-year term with a four-year vesting schedule, promoting long-term employment and commitment to Pacira.
What products does Pacira currently offer?
Pacira offers EXPAREL, ZILRETTA, and iovera, all aimed at providing effective, non-opioid pain management solutions.
What is the significance of Nasdaq Listing Rule 5635(c)(4)?
This rule allows for the granting of stock awards to new hires without stockholder approval, facilitating a smoother process for companies looking to incentivize their employees.
